Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients

Chinese Medical Journal

Volumn 125, Issue 23, 2012, Pages 4226-4232

  Qiu, Kui ^a   Tian, Hui ^a   Wang, Wei ^a   Hu, Xiao Peng ^a   Li, Xiao Bei ^a   Gong, Li Li ^a   Luo, Wei ^a   Liu, Li Hong ^a   Zhang, Xiao Dong ^a   Yin, Hang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chinese renal transplant recipients; Enteric coated mycophenolate sodium; Limited sampling strategy; Pharmacokinetics

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG CLEARANCE; ENTERIC COATED TABLET; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; KIDNEY TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; PREDICTION; STATISTICAL MODEL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADRENAL CORTEX HORMONES; ADULT; AGED; CYCLOSPORINE; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; YOUNG ADULT;

EID: 84870745544     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.23.012     Document Type: Article

References (23)

1. Pelletier RP, Akin B, Henry ML, Bumgardner GL, Elkhammas EA, Rajab A, et al. The impact of mycophenolate mofetil dosing patterns on outcomes in renal transplantation. Clin Transplant 2003; 17: 200-205.
2. Sánchez Fructuoso A, Calvo N, Moreno MA, Conesa J, Barrientos A. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil. Transplant Proc 2007; 39: 2194-2196.
3. Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation 2011; 91: 470-478.
4. Reyes H, Hernández AM, Valverde S, Cataneo A, Mendoza A, Barrera I. Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. Pediatr Transplantation 2010; 14: 746-752.
5. Baraldo M, Cojutti PG, Isola M, Feruglio MT, Tursi V, Livi U, et al. Validation of limited sampling strategy for estimation of mycophenolic acid exposure during the first year after heart transplantation. Transplant Proc 2009; 41: 4277-4284.
6. Zhang Q, Tao YF, Zhu YB, Zhu D. Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, two-way crossover study. Clin Ther 2010; 32: 171-178.
7. Jiao Z, Zhong JY, Zhang M, Shi XJ, Yu YQ, Lu WY. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: Pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol 2007; 63: 27-37.
8. Yu ZC, Zhou PJ, Xu D, Wang XH, Chen HZ. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol 2006; 62: 446-452.
9. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinetic Biopharm 1981; 4: 503-512.
10. Gong NQ, Ming CS, Zeng FJ, Zhang WJ, Lin ZB, Zhou P, et al. Renal function of donors and recipients after living donor kidney transplantation in a Chinese cohort. Chin Med J 2011; 124: 1290-1295.
11. Sommerer C, Müller-Krebs S, Schaier M, Glander P, Budde K, Schwenger V, et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010; 4: 346-357.
12. Capone D, Tarantino G, Kadilli I, Polichetti G, Basile V, Federico S, et al. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving entericcoated mycophenolate sodium (EC-MPS) and cyclosporine. Nephrol Dial Transplant 2011; 9: 1-7.
13. Tsang WK, Tong KL, Yeung S, Lee W, Chan HW. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients. Transplant Proc 2000; 32: 1755-1756.
14. Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005; 19: 199-206.
15. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006; 82: 1413-1418.
16. Hosotsubo H, Takahara S, Imamura R, Kyakuno M, Tanaka T, Yazawa K, et al. Analytic validation of the enzyme multiplied immunoassay technique for the determination of mycophenolic acid inplasma from renal transplant recipients compared with a high-performance liquid chromatographic assay. Ther Drug Monit 2001; 23: 669-674.
17. Sabbatini M, Capone D, Gallo R, Pisani A, Polichetti G, Tarantino G, et al. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol 2009; 23: 617-624.
18. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 36: 315-324.
19. Sumethkul V, Na-Bangchang K, Kantachuvesiri S, Jirasiritham S. Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. Transplant Proc 2005; 37: 861-863.
20. Shah T, Tellez-Corrales E, Yang JW, Qazi Y, Wang J, Wilson J, et al. The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of hispanic ethnicity. Ther Drug Monit 2011; 33: 45-49.
21. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-315.
22. Cattaneo D, Cortinovis M, Baldelli S, Bitto A, Gotti E, Remuzzi G, et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007; 2: 1147-1155.
23. Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, et al. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus. Expert Opin Pharmacother 2010; 11: 689-699.